| Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... New England Journal of Medicine 375 (19), 1823-1833, 2016 | 9711 | 2016 |
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ... The Lancet 387 (10027), 1540-1550, 2016 | 6767 | 2016 |
| Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes GE Meininger, R Scott, M Alba, Y Shentu, E Luo, H Amin, MJ Davies, ... Diabetes care 34 (12), 2560-2566, 2011 | 220 | 2011 |
| Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung … LG Paz-Ares, A Luft, A Tafreshi, M Gumus, J Mazieres, B Hermes, ... Journal of Clinical Oncology 36 (15_suppl), 105-105, 2018 | 157 | 2018 |
| Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial RS Herbst, P Baas, JL Perez-Gracia, E Felip, DW Kim, JY Han, JR Molina, ... Annals of Oncology 30 (2), 281-289, 2019 | 104 | 2019 |
| Statistical issues and recommendations for clinical trials conducted during the COVID-19 pandemic RD Meyer, B Ratitch, M Wolbers, O Marchenko, H Quan, D Li, C Fletcher, ... Statistics in Biopharmaceutical Research 12 (4), 399-411, 2020 | 83 | 2020 |
| The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*† W Yang, Y Guan, Y Shentu, Z Li, AO JOHNSON‐LEVONAS, SS Engel, ... Journal of Diabetes 4 (3), 227-237, 2012 | 76 | 2012 |
| Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS)≥ 50% enrolled in KEYNOTE-024. JR Brahmer, D Rodriguez-Abreu, AG Robinson, R Hui, T Csõszi, A Fülöp, ... Journal of Clinical Oncology 35 (15_suppl), 9000-9000, 2017 | 73 | 2017 |
| Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001,-010, and-024 C Aggarwal, DR Abreu, E Felip, E Carcereny, M Gottfried, T Wehler, ... Annals of Oncology 27, vi363, 2016 | 68 | 2016 |
| Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 … V Fonseca, B Staels, JD Morgan II, Y Shentu, GT Golm, ... Journal of Diabetes and its Complications 27 (2), 177-183, 2013 | 58 | 2013 |
| A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes MS Kipnes, P Hollander, K Fujioka, I Gantz, T Seck, N Erondu, Y Shentu, ... Diabetes, Obesity and Metabolism 12 (6), 517-531, 2010 | 55 | 2010 |
| Principal stratum strategy: potential role in drug development B Bornkamp, K Rufibach, J Lin, Y Liu, DV Mehrotra, S Roychoudhury, ... Pharmaceutical Statistics 20 (4), 737-751, 2021 | 51 | 2021 |
| A note on dichotomization of continuous response variable in the presence of contamination and model misspecification Y Shentu, M Xie Statistics in medicine 29 (21), 2200-2214, 2010 | 47 | 2010 |
| Efficacy and tolerability of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control: A randomized, double-blind … P Hartley, Y Shentu, P Betz-Schiff, GT Golm, CMC Sisk, SS Engel, ... Drugs & aging 32, 469-476, 2015 | 40 | 2015 |
| A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus … RG Moses, E Round, Y Shentu, GT Golm, EA O'neill, I Gantz, SS Engel, ... Journal of Diabetes 8 (5), 701-711, 2016 | 33 | 2016 |
| OA03. 07 KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab R Herbst, E Garon, DW Kim, BC Cho, S Gadgeel, H Léna, A Gúrpide, ... Journal of Thoracic Oncology 12 (1), S254-S255, 2017 | 32 | 2017 |
| Assessing the impact of COVID-19 on the clinical trial objective and analysis of oncology clinical trials—application of the estimand framework E Degtyarev, K Rufibach, Y Shentu, G Yung, M Casey, S Englert, F Liu, ... Statistics in Biopharmaceutical Research 12 (4), 427-437, 2020 | 29 | 2020 |
| KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS)≥ 50% M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csoszi, A Fülöp, ... Annals of Oncology 27, vi578, 2016 | 26 | 2016 |
| PD1. 06 (also presented as P2. 41): pembrolizumab vs docetaxel for previously treated NSCLC (KEYNOTE-010): archival vs new tumor samples for PD-L1 assessment RS Herbst, P Baas, JL Perez-Gracia, E Felip, DW Kim, JY Han, J Molina, ... Journal of Thoracic Oncology 11 (10), S174-S175, 2016 | 25 | 2016 |
| Adaptive informational design of confirmatory phase III trials with an uncertain biomarker effect to improve the probability of success C Chen, N Li, Y Shentu, L Pang, RA Beckman Statistics in Biopharmaceutical Research 8 (3), 237-247, 2016 | 21 | 2016 |